Cardiology

Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.

Evolocumab reshapes arterial plaque, reducing cardiovascular risk by lowering microcalcification and shifting plaque composition over 18 months.

MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.

NewAmsterdam Pharma announces promising Phase 3 results for obicetrapib, showing significant LDL-C reduction in patients with ASCVD and/or HeFH.

FDA approves 12.5 mg chlorthalidone tablets, enhancing hypertension treatment options and aligning with clinical guidelines for better patient outcomes.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

The FDA accepted the NDA for oral semaglutide 25 mg, a potentially revolutionary daily treatment for weight management and cardiovascular risk reduction.

After following up twice between ages 17 and 24, investigators discovered a three- to five-fold increase in blood glucose and insulin resistance, predicting a matching increase in heart disease risk.

Patients provided with a Post-Acute Care Hypertension consultation and a method of daily medication reminders presented lower blood pressure on follow-up.

FDA further postpones action date for elamipretide, a potential treatment for Barth syndrome, as discussions on labeling progress.

Data suggest that etripamil may be more effective than vagal maneuvers and oral prophylaxis, minimizing emergency department visits.

New research links increased dietary selenium intake to reduced cardiovascular disease risk, highlighting its potential benefits for heart health.

Using the American Heart Association’s Life’s Essential 8 model, researchers indicated that preventative action early in life can reduce chances of developing cardiovascular disease later.

A major factor of type 2 diabetes mellitus, dyslipidemia can potentially be prevented by closely monitoring lipid profiles.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

Researchers indicated an association between the index and 365-day mortality.

A secondary analysis of the data collected by the DASH-Sodium trial indicates that dieting and sodium intake limits are additive in their effects on ASCVD risk.

Orchestra BioMed’s Breakthrough Device designation could apply to nearly 8 million patients with uncontrolled hypertension and increased cardiovascular risk

The model could allow cardiologists to inform and prepare patients before symptoms of hypertrophic cardiomyopathy make themselves known.

Christie M. Ballantyne, MD, discusses the role of plozasiran in managing elevated triglycerides and reducing pancreatitis risk.

The scalability and portability of these ECGs could also allow for a community-based approach to heart healthcare.

Anita Radhakrishnan, MD, leads a community screening effort to detect early heart disease in underserved populations in Pittsburgh.

Our top 5 headlines spotlight FDA approvals for maralixibat and dupilumab, plus key trial results in diabetes, cardiovascular disease, and retinal vein occlusion.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.